A5021523822- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Angiogenesis and VEGF in Cancer
- Breast Cancer Treatment Studies
- Lipid metabolism and disorders
- CAR-T cell therapy research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Cancer, Hypoxia, and Metabolism
- Growth Hormone and Insulin-like Growth Factors
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Multiple Myeloma Research and Treatments
- Protease and Inhibitor Mechanisms
- Ovarian cancer diagnosis and treatment
- Blood Coagulation and Thrombosis Mechanisms
- Lymphoma Diagnosis and Treatment
- S100 Proteins and Annexins
- Glycosylation and Glycoproteins Research
- Apelin-related biomedical research
- CRISPR and Genetic Engineering
- Brain Metastases and Treatment
- Glioma Diagnosis and Treatment
Cellectis (United States)
2020-2022
Bristol-Myers Squibb (Switzerland)
2019
Regeneron (United States)
2013-2016
La Roche College
2013-2015
University of California, San Francisco
2013
University of Tennessee Health Science Center
2013
St. Jude Children's Research Hospital
2013
Methodist Hospital
2013
Baylor College of Medicine
2013
Roche (Switzerland)
2010-2013
R1507 is a selective, fully human, recombinant monoclonal antibody (immunoglobulin G1 subclass) against insulin-like growth factor-1 receptor (IGF-1R). The strong preclinical evidence supporting coinhibition of IGF-1R and epidermal factor (EGFR) as anticancer therapy prompted this study.
Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2 study assessed fedratinib in patients with intermediate- or high-risk myelofibrosis (MF) who were resistant intolerant to prior ruxolitinib per investigator assessment. Patients received 400 mg/day 28-day cycles. outcomes initially reported using a last-observation-carried forward (LOCF) analysis "Per Protocol" population. This updated of employs intention-to-treat principles without LOCF for all treated...
Nesvacumab (REGN910) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Ang2 with high affinity, but shows no binding to Ang1. The main objectives of this trial were determine safety, tolerability, dose-limiting toxicities (DLT), recommended phase II dose (RP2D) nesvacumab.Nesvacumab was administered intravenously every two weeks escalations from 1 20 mg/kg in patients advanced solid tumors.A total 47 treated...
We conducted a randomized phase III study to determine whether patients with early breast cancer would benefit from the addition of capecitabine (X) standard regimen doxorubicin (A) plus cyclophosphamide (C) followed by docetaxel (T).Treatment comprised eight cycles AC→T (T dose: 100 mg/m(2) on day 1) or AC→XT (X 825 twice daily, days 1-14; T 75 1). The primary endpoint was 5-year disease-free survival (DFS).Of 2,611 women, 1,304 were randomly assigned receive and 1,307 AC→XT. After median...
GH deficiency is a common late complication in survivors of pediatric malignancies, particularly those who are treated with radiation (RT) to the hypothalamic-pituitary region. Nonetheless, few reports have assessed final height outcomes GH. In present study, we investigated which patient and treatment variables correlate change sd score (SDS) large cohort cancer
Abstract Background: Combination regimens incorporating anthracyclines and taxanes are among the most effective for EBC particularly suitable pts with high-risk disease. Significant efficacy benefit has been shown in phase III trials integrating capecitabine (X) into anthracycline/taxane-containing (neo)adjuvant (Joensuu H, et al. Lancet Oncol 2009; Steger G, ASCO 2010). We present first results of a large, randomized, multicenter study comparing adjuvant doxorubicin plus cyclophosphamide...
It has become increasingly evident that the generation of cell surface proteases including plasmin is fundamental to a wide variety in vivo biological processes. Cell receptors allow for specific controlled proteolysis, provide protection from inhibitors, and enhance catalytic efficiency. Here we describe one such receptor, annexin II, which serves as coreceptor tissue plasminogen activator found on types endothelial cells, some tumor monocytes macrophages, neuronal cells. Evidence indicates...
2502 Background: Dll4, a Notch receptor ligand, may have role in tumor angiogenesis and is an emerging anticancer target. REGN421 (R) fully human IgG 1 mAb that binds Dll4 disrupts Notch-mediated signaling. Methods: Primary objectives of the dose escalation (3+3 design) trial were to determine safety recommended phase II (RP2D) R patients (pts) with advanced cancer. was given IV at doses 0.25, 0.5, 1, 2 4mg/kg every 3 weeks (Q3W) or 0.75, 1.5, 3mg/kg (Q2W). Secondary PK, immunogenicity,...
2516 Background: REGN1400 (R) is a fully human mAb targeting ErbB3. Preclinically, dual inhibition of ErbB3 and EGFR confers augmented antitumor potency. This first-in-human dose escalation trial evaluates safety, tolerability, recommended phase 2 (RP2D), pharmacokinetics (PK) anti-tumor activity R alone or combined with erlotinib (E) cetuximab (C) in NSCLC, CRC SCCHN pts who progressed on prior E C. Methods: study used 2-stage 3+3 design. administered IV Q2W at doses 3, 10, 20 mg/kg. Once...
7057 Background: MF is a life-threatening MPN for which RUX the only approved treatment (Tx) option. Patients (pts) who are relapsed/refractory (R/R) or intolerant to have particularly high unmet medical need. FEDR an oral selective JAK2 inhibitor active against wt and mut JAK2. The JAKARTA-2 study demonstrated ≥35% spleen volume responses (SVR) in pts resistant per investigator assessment. This reanalysis employs more stringent definition of failure than used previous analysis. Methods:...
BackgroundWe conducted a phase I study to estimate the maximum tolerated dose and describe dose-limiting toxicities pharmacokinetics of oral capecitabine rapidly disintegrating tablets given concurrently with radiation therapy children newly diagnosed brainstem or high-grade gliomas.
7584 Background: R1507 is a monoclonal antibody which specifically inhibits IGF-IR. NO21160 was randomized, placebo controlled phase II trial of two doses and schedules + erlotinib as second/third-line therapy for advanced non-small cell lung cancer. The primary endpoint, comparison PFS rate at 12 weeks, not met (HR=0.99 16 mg q3W 1.17 9 qW) in an unselected patient population. A panel biomarkers were analyzed attempt to identify potential predictive markers define subset the patients who...
7527 Background: R1507 (Hoffman LaRoche) is a selective, fully human, recombinant monoclonal antibody (IgG1 subclass) against IGF-1R. Based on strong pre-clinical evidence supporting co-inhibition of IGF-1R and epidermal growth factor receptors, we conducted randomized study with erlotinib (E). Methods: Advanced NSCLC patients progression following 1 or 2 prior chemotherapy regimens, ECOG PS 0-2, measurable disease were eligible. Patients to receive (150 mg PO QD) in combination either...
2522 Background: Nesvacumab (N) is a selective, human Ang-2 MAb, that potently blocks Ang2 signaling through the Tie2 receptor. Ziv-aflibercept (Z) recombinant fusion protein and decoy receptor for VEGF-A, VEGF-B, placental growth factor. In mouse xenograft models, N+Z significantly inhibited tumor angiogenesis compared to either agent alone. Methods: This phase 1b dose escalation study seeks evaluate safety, pharmacokinetic (PK), pharmacodynamics (PD), find recommended 2 (RD), explore...
Abstract Background: Uterine Serous Carcinoma (USC) is an aggressive subtype of endometrial cancer characterized by ubiquitous TP53 mutations and high replication stress. The resulting dependency on DNA damage repair cell cycle checkpoints triggers sensitivity to the abrogation G2 checkpoint using Wee1 inhibitors (Wee1i) such as Azenosertib. Wee1i has been associated with levels Cyclin E1, which may result from gene amplification CCNE1 or alteration its ubiquitin ligase FBXW7 1. In addition,...